Guardian Bio — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Guardian Bio is a private, pre-clinical stage biotech developing a novel dendritic cell therapy platform for solid tumors. The company's approach centers on generating 'Guard-cDC1s' from patient-derived stem cells to overcome a key bottleneck in cancer immunity—the dysfunction of critical antigen-presenting cells. Founded by a team with expertise in immunology, business, and pioneering dendritic cell research, the company is positioned to address a significant unmet need in oncology, though it faces the typical high-risk, high-reward path of novel cell therapy development.

OncologySolid Tumors

Technology Platform

Proprietary process to generate conventional type 1 dendritic cells (cDC1s), termed Guard-cDC1s, from a patient's own hematopoietic stem cells for use as an autologous cell therapy to restore anti-cancer immunity.

Opportunities

The significant unmet need in late-stage solid tumors and the potential for dendritic cell therapy to serve as a foundational, combination-friendly immunotherapy create a large market opportunity.

Advances in cell manufacturing and a deeper understanding of dendritic cell biology provide a more favorable development environment than earlier attempts in the field.

Risk Factors

High scientific risk associated with a novel cell therapy approach, including challenges in manufacturing, delivery, and demonstrating efficacy in the immunosuppressive solid tumor microenvironment.

The company also faces intense competition in immuno-oncology and is dependent on raising substantial capital to fund development.

Competitive Landscape

Guardian Bio operates in the competitive cell therapy and cancer vaccine space. It differentiates by focusing on generating specific cDC1s, a approach distinct from earlier monocyte-derived DC vaccines and current T-cell focused therapies like CAR-T. Competitors include other DC therapy developers (e.g., Immunicum, DCprime) and a broad array of immuno-oncology companies targeting solid tumors.

More companies in Cell & Gene Therapy →More companies in United States →